Immune-Modulating Therapies for Type 1 Diabetes

In Type 1 diabetes, the immune system attacks insulin-producing beta cells in the pancreas, leading to insulin deficiency. Immune-modulating therapies aim to prevent or slow this autoimmune destruction. Strategies include using monoclonal antibodies to block specific immune cells, promoting immune tolerance to beta cells, and harnessing regulatory T cells to reduce inflammation. Early-stage clinical trials have shown potential in preserving beta cell function in newly diagnosed patients. The ultimate goal of immune modulation is to either prevent the onset of Type 1 diabetes in at-risk individuals or delay disease progression by preserving endogenous insulin production.